{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:19Z","timestamp":1793120059808,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cgh.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:32:18Z","timestamp":1781911938000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["No Impact of Low-Dose Nivolumab Addition to JNJ-73763989 on Hepatitis B Surface Antigen Declines in Chronic Hepatitis B: The OCTOPUS-1 Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila","family":"Akhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camellia","family":"Diba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huybrecht","family":"T\u2019jollyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-I","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nalpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Guinard-Azadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Lathouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"De Creus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.06.018_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep4.1875","article-title":"Aiming for functional cure with established and novel therapies for chronic hepatitis B","volume":"6","author":"Choi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2026.06.018_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.06.018_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.018_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000534535","article-title":"Possibility of PD-1\/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection","volume":"42","author":"Su","year":"2024","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2026.06.018_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B:REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.018_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.cgh.2026.06.018_bib14","article-title":"Immune mechanisms underlying hepatitis B surface antigen seroclearance in chronic hepatitis B patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cgh.2026.06.018_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)02244-X","article-title":"Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study","volume":"80","author":"Thys","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)02237-2","article-title":"Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients.","volume":"80","author":"Verheijden","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/cpt.3690","article-title":"Population pharmacokinetics of siRNA JNJ-73763989 in healthy participants and patients with chronic hepatitis B","volume":"118","author":"Ogawa","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.018_bib18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cgh.2026.06.018_bib19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.06.018_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","article-title":"Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers","volume":"12","author":"Rajan","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cgh.2026.06.018_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.06.018_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cgh.2026.06.018_bib24","doi-asserted-by":"crossref","first-page":"101360","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cgh.2026.06.018_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cgh.2026.06.018_bib26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/HEP.0000000000001006","article-title":"A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative","volume":"81","author":"Qian","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.06.018_bib27","series-title":"Presented at American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Metting","first-page":"15","article-title":"Preliminary antiviral efficacy and safety of repeat dosing of imdusiran (ab-729) followed by vtp-300 with or without nivolumab in virally suppressed, non-cirrhotic subjects with chronic Hepatitis B (CHB)","author":"Wong","year":"2024"},{"key":"10.1016\/j.cgh.2026.06.018_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2026.06.018_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/psp4.13129","article-title":"Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice","volume":"13","author":"Sandra","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cgh.2026.06.018_bib30","article-title":"Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study","volume":"7","author":"Gane","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.06.018_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/gutjnl-2025-336592","article-title":"Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg positive chronic hepatis B virus (HBV) infection: the phase 2 REEF-IT study","volume":"75","author":"Kennedy","year":"2026","journal-title":"Gut"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:02:19Z","timestamp":1786017739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S1542356526004714"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.018","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No Impact of Low-Dose Nivolumab Addition to JNJ-73763989 on Hepatitis B Surface Antigen Declines in Chronic Hepatitis B: The OCTOPUS-1 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}